Literature DB >> 1203889

Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases.

J M Hill, E Loeb, A MacLellan, N O Hill, A Khan, J J King.   

Abstract

Following the prior work of Rosenberg et al, Rosenberg and VanCamp, and Speer et al, we started clinical trials with cis-dichlorodiammineplatinum(II) in April 1971. Marked tumor regression was noted in several malignant diseases in these initial clinical studies which were reported at the Chemotherapy Congress in Prague, August 1971. At the present time over 178 patients have been treated wihhis durg for a variety of malignant conditions. Approximately half of these patients received the platinum compound alone and the other half received it in combination with four other chemotherapeutic agents...

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1203889

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  31 in total

1.  Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study.

Authors:  L S Ashby; W R Shapiro
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

Review 2.  New drugs under clinical evaluation in the United States.

Authors:  S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.

Authors:  Srinevas K Reddy; Colleen Reilly; Min Zhan; Ayse L Mindikoglu; Yixing Jiang; Barton F Lane; H Richard Alexander; William J Culpepper; Samer S El-Kamary
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

4.  The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells.

Authors:  J L Collins; M S Kao
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma.

Authors:  P K Buamah; A Howell; H Whitby; E S Harpur; A Gescher
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Cisplatin plus cytosine arabinoside in adults with malignant gliomas.

Authors:  D J Stewart; M T Richard; B Benoit; H Hugenholtz; N Russell; J Dennery; E Peterson; Z Grahovac; G Belanger; S Aitkens
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

7.  Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma.

Authors:  J Z Fuks; M J Egorin; J Aisner; D A Van Echo; S Ostrow; N R Bachur; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Cisplatin disposition in children and adolescents with cancer.

Authors:  W R Crom; W E Evans; C B Pratt; N Senzer; M Denison; A A Green; F A Hayes; G C Yee
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

10.  Carboplatin-Induced Bilateral Papilledema: A Case Report.

Authors:  N Fischer; J Stuermer; B Rodic; M Pless
Journal:  Case Rep Oncol       Date:  2009-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.